Disclaimer: This content is provided for educational purposes only and is not a substitute for independent clinical judgment. Always consult official product monographs and prescribing information before making treatment decisions. Do not delay or disregard professional medical advice because of information on this site. Use of this resource does not establish a physician–patient relationship. See the full disclaimer for details.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of atenolol due to OCT1/OCT2 inhibition. Monitor for signs of toxicity (hypotension, bradycardia). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Avoid combination - decreased level of abemaciclib due to 3A4 induction. Choose an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Avoid combination - increased level of abemaciclib due to 3A4 inhibition. Choose an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of both agents due to 3A4 inhibition. Monitor for signs of toxicity. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of abemaciclib due to 3A4 inhibition. Use lowest dose and shortest duration as clinically indicated. Monitor for signs of abemaciclib toxicity. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of gabapentin due to OCT2 inhibition. Monitor for signs of toxicity (sedation, lethargy). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of guanfacine due to 3A4/OCT1/OCT2 inhibition. Monitor for signs of toxicity (hypotension, bradycardia, sedation). If initiating therapy, titrate slowly. If already established on therapy, 50% dose reduction advised. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Avoid combination - increased level of abemaciclib due to 3A4 inhibition. Choose an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.



